Diagnostic Testing & Technology Report
Diagnostic Testing & Technology Report contains up-to-the-minute information AND unique perspectives on where diagnostic testing is headed, covering every innovation, new product, manufacturer, market and end-user application. Each monthly issue provides an unbeatable blend of news, analysis, statistics, and forecasts. Keep up with the latest trends in esoteric lab testing and what the hottest new tests are worth to your bottom line. Plus, find out about the strategies that individual companies are implementing now to win the fight for specific local markets and which sector has the most potent resources and best game plan for the long term.
February 2010 - Table of Contents
Quidel (San Diego) is moving from the bedside to the bench.
Genomic Health (Redwood City, Calif.) expects to realize 2009 revenue of $149.5 million.
Predictive Biosciences (Lexington, Mass.) has acquired OncoDiagnostic Laboratory (Cleveland), a CLIA-certified anatomic pathology and molecular diagnostics lab serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians.
Cepheid has been granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Xpert Flu A Panel test.
New clinical guidelines issued by the American Diabetes Association (ADA) include the recommendation that the hemoglobin A1C test be used for diagnosing diabetes.
Abbott Diagnostics (Abbott Park, Ill.) has received CE Mark (Conformite Europeene) certification for a blood test that can aid in the assessment of epithelial ovarian cancer.
Philips (Amsterdam) and bioMerieux (Marcy L’Etoile, France) have partnered to develop a line of point-of-care tests.
When asked to compare Genomic Health’s business model to that of other diagnostics companies, President and CEO Kim Popovits doesn’t have an easy answer.
Life Technologies (Carlsbad, Calif.), the company created by the 2008 roll-up of Invitrogen and Applied Biosystems, will report revenue of approximately $3.2 billion for 2009.
Quest Diagnostics (Madison, N.J.) continues to expand its portfolio of cancer diagnostics.
Researchers have identified an inherited genetic variant associated with aggressive prostate cancer that could one day be used to help distinguish between aggressive and slow-growing forms of the disease at an early stage.
Medicare spending continues to grow even as the growth in nation’s total health tab slowed, in part due to the economic recession, according to the latest annual report on national health spending from the Office of the Actuary at the Centers for Medicare and Medicaid Services.
New York-based MVP Health Care and Blue Cross of Idaho are the two latest payers using the InterQual Molecular Diagnostics Criteria system, from McKesson’s Advanced Diagnostics Management Division (ADM), which uses reviews of evidence-based medicine to assess appropriateness and utilization patterns in making coverage decisions.
The 16 stocks in the G-2 Diagnostic Stock Index climbed an unweighted average of 31 percent in 2009 versus respective gains of 44 percent and 23 percent for the Nasdaq and the S&P 500.
Learn how clinical laboratories can capitalize on molecular diagnostics. . . .
Diagnostic Testing & Technology Report is part of...
Focus Areas |
Product Group |
 G2 Reports Medical Lab Management |
Newsletters |